Accelerated Pharma (Accelerated Pharma) Debt-to-Revenue : N/A (As of Mar. 2017)

View and export this data going back to 2016. Start your Free Trial

What is Accelerated Pharma Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Accelerated Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2017 was $3.69 Mil. Accelerated Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2017 was $1.23 Mil. Accelerated Pharma's annualized Revenue for the quarter that ended in Mar. 2017 was $0.00 Mil.

Accelerated Pharma Debt-to-Revenue Historical Data

The historical data trend for Accelerated Pharma's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerated Pharma Debt-to-Revenue Chart

Accelerated Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Debt-to-Revenue

N/A

Accelerated Pharma Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
Debt-to-Revenue	Get a 7-Day Free Trial			N/A	N/A	N/A	N/A	N/A

Competitive Comparison of Accelerated Pharma's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Accelerated Pharma's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Accelerated Pharma's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Accelerated Pharma's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Accelerated Pharma's Debt-to-Revenue falls into.

Accelerated Pharma Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Accelerated Pharma's Debt-to-Revenue for the fiscal year that ended in Dec. 2016 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(3.38	+	1.211)	/	N/A
	=	N/A

Accelerated Pharma's annualized Debt-to-Revenue for the quarter that ended in Mar. 2017 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(3.685	+	1.229)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2017) Revenue data.

Accelerated Pharma Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Accelerated Pharma's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Accelerated Pharma (Accelerated Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Accelerated Pharma Inc (NAS:ACCP) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Accelerated Pharma Inc, is a Delaware corporation organized on May 12, 2014. It is a biopharmaceutical company focused on utilizing its genomic technology to enhance the development and commercialization of pharmaceutical products. Its lead product candidate is Picoplatin, a new generation platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications.

Accelerated Pharma (Accelerated Pharma) Headlines

No Headlines